Alpha Fusion
Unlock the potential of alpha-particle therapy for human health.
Osaka, Japan · $9.2M raised
- Headquarters
- Osaka
- Employees
- 11–50
- Business Model
- B2B
- Website
- alpha-fusion.com
- Total Funding
- $9.2M
- Last Round
- $9.2M Series BAug 2023
- Rounds
- 1
About
Alpha Fusion Inc. is a Japan-based clinical-stage biotech company commercializing Targeted Alpha Therapy (TAT) based on astatine-211 (211At). The company integrates expertise in radiochemistry, drug discovery, and clinical medicine to develop innovative radiopharmaceuticals that destroy cancer cells with precision while minimizing damage to surrounding healthy tissue. Alpha Fusion has multiple pipelines leveraging astatine-211, with two programs currently in clinical trials and company-sponsored trials planned from 2026. The company collaborates with Osaka University, Mitsubishi Tanabe Pharma, and Veneno Technologies.
Summary
Alpha Fusion is a Biotechnology company based in Osaka, Japan. It has raised $9.2M in total across 1 round, most recently a $9.2M Series B round in Aug 2023.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2023
Similar Companies
Leading innovative radiopharmaceutical company in China developing next-generation radiopharmaceu...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.